Cargando…

Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events

BACKGROUND: FGF21 (fibroblast growth factor 21), a novel hepatokine regulating lipid metabolism, has been linked to atherosclerotic disease. However, whether this relationship exists in patients without nonalcoholic fatty liver disease is unclear. We assessed the association between serum FGF21 leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Liang, Qian, Lingling, Zhang, Lei, Zhang, Jing, Zhou, Jia, Li, Yuehua, Hou, Xuhong, Fang, Qichen, Li, Huating, Jia, Weiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428997/ https://www.ncbi.nlm.nih.gov/pubmed/32431189 http://dx.doi.org/10.1161/JAHA.119.015226

Ejemplares similares

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
por: Wu, Guangyu, et al.
Publicado: (2017)

Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders
por: Qian, Lingling, et al.
Publicado: (2020)

Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
por: Long, Xiaoxue, et al.
Publicado: (2021)

Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases
por: Wu, Liang, et al.
Publicado: (2017)

FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China
por: Liu, Dan, et al.
Publicado: (2021)

Identification of Sp1 as a Transcription Activator to Regulate Fibroblast Growth Factor 21 Gene Expression
por: Chen, Shuqin, et al.
Publicado: (2017)

Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat
por: Li, Huating, et al.
Publicado: (2018)

Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels
por: Fang, Qichen, et al.
Publicado: (2013)

Sodium Butyrate Stimulates Expression of Fibroblast Growth Factor 21 in Liver by Inhibition of Histone Deacetylase 3
por: Li, Huating, et al.
Publicado: (2012)

Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis
por: Rasool, Abid, et al.
Publicado: (2017)

Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients
por: Zhang, Xiaoyan, et al.
Publicado: (2015)

Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes
por: Lu, Jingyi, et al.
Publicado: (2015)

Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease
por: Mohammadi, Afshin, et al.
Publicado: (2011)

Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis
por: Xu, Xin, et al.
Publicado: (2015)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
por: Li, Xinyue, et al.
Publicado: (2021)

Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose
por: Zhang, Jing, et al.
Publicado: (2017)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
por: Finney, Alexandra C., et al.
Publicado: (2023)

Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation
por: Ye, Dewei, et al.
Publicado: (2016)

Decreased Abundance of Akkermansia muciniphila Leads to the Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes
por: Zhang, Jing, et al.
Publicado: (2021)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis
por: Sinn, Dong Hyun, et al.
Publicado: (2016)

Novel predictors of early atherosclerosis in nonalcoholic fatty liver disease
por: Abdulaziz, Badawy Abdulkhalik, et al.
Publicado: (2023)

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
por: Tian, Haoyu, et al.
Publicado: (2023)

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
por: Alisi, Anna, et al.
Publicado: (2013)

Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway
por: Dou, Jianxin, et al.
Publicado: (2014)

Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
por: Kwok, Kelvin H. M., et al.
Publicado: (2017)

Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease
por: Taylan, Gökay, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases
por: Zhang, Daqing, et al.
Publicado: (2023)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis
por: Kang, Min Kyoung, et al.
Publicado: (2015)

Nonalcoholic Fatty Liver Disease in Hispanic Youth With Dysglycemia: Risk for Subclinical Atherosclerosis?
por: Bacha, Fida, et al.
Publicado: (2017)

Association and Prediction of Subclinical Atherosclerosis by Nonalcoholic Fatty Liver Disease in Asymptomatic Patients
por: Bae, Ye Seul, et al.
Publicado: (2020)

Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Lu, Hongyun, et al.
Publicado: (2013)

Cholic Acid Enhances Visceral Adiposity, Atherosclerosis and Nonalcoholic Fatty Liver Disease in Microminipigs
por: Yamada, Sohsuke, et al.
Publicado: (2017)

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2019)

Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial
por: Zhang, Lei, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study
por: Han, Jie, et al.
Publicado: (2019)

The impact of obstructive sleep apnea on nonalcoholic fatty liver disease
por: Tang, Haiying, et al.
Publicado: (2023)

Fibroblast growth factor 21 inhibits atherosclerosis in apoE−/− mice by ameliorating Fas-mediated apoptosis
por: Yan, Xinxin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5qm1l29gsnbscbl7m8ecp8ttni